Effects of integrin-targeted photodynamic therapy on pancreatic carcinoma cell

Figure 1 The fluorescence expression of SW1990 cells with the imaging of quantum dots-arginine-glycine-aspartic acid probe. A: Quantum dots-arginine-glycine-aspartic acid probe imaging; B: Original image; C: 4',6-diamidino-2-phenylindole, dihydrochloride dyeing; D: Integrated image.

Figure 2 The fluorescence imaging of SW1990 cells with quantum dots-arginine-glycine-aspartic acid probe at the block of excess arginine-glycine-aspartic acid peptide. A: Quantum dots- arginine-glycine-aspartic acid probe imaging; B: Original image; C: 4',6-diamidino-2-phenylindole, dihydrochloride dyeing; D: Integrated image.

Figure 3 The morphologic changes of cells observed under fluorescence microscope with the stain of DAPI after treated seperately (× 100). A: Blank group; B: Light group; C: Quantum dots-arginine-glycine-aspartic acid group; D: Photodynamic therapy group.

Figure 4 The cell apoptosis of cells after treated separately. A: Control group; B: Light group; C: Quantum dots-arginine-glycine-aspartic acid group; D: Photodynamic therapy (PDT) group.

Figure 5 Cell cycle of cells after treated separately. A: Control group; B: Light group; C: Quantum dots-arginine-glycine-aspartic acid group; D: Photodynamic therapy group.

Figure 6 Number of cells producing reactive oxygen species after treated separately. A: Control group; B: Light group; C: Quantum dots-arginine-glycine-aspartic acid group; D: Photodynamic therapy group.

Figure 7 Expression of myeloid cell leukemia-1, protein kinase B and tumor necrosis factor-related apoptosis-inducing ligand mRNA in each group by reverse transcription-polymerase chain reaction analysis. A: Control group; B: Light group; C: Quantum dots-arginine-glycine-aspartic acid group; D: Photodynamic therapy group. Mcl-1: Myeloid cell leukemia-1; Akt: Protein kinase B; TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.